Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence
Sign Up to like & getrecommendations! Published in 2017 at "Medical Oncology"
DOI: 10.1007/s12032-017-0895-4
Abstract: Nivolumab offers a statistically superior survival benefit over docetaxel in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer (NSCLC). However, we unexpectedly encountered “tumor flare” that was associated with initially increased tumor… read more here.
Keywords: nivolumab treatment; tumor flare; irradiated field; tumor ... See more keywords